ICAAC 45th

Title Content type
Efficacy, Safety, and Tolerability of three Different Dosing Regimens of BAL8557 Vs. Fluconazole in a Double-Blind, Randomized, Multicenter Trial for the Treatment of Esophageal Candidiasis in Immunocompromised Adults (click for details)
In vivo Efficacy of the triazole BAL8557 (BAL) Compared to Voriconazole (VOR), Itraconazole (ITC) and Caspofungin (CAS) By a New qPCR and Quantitative Culture in a Neutropenic Murine Model of Aspergillus flavus (click for details)
Dose Response Curves and Dose Fractionation Studies with BAL8557 in a Murine Model of Disseminated Candidiasis (click for details)
Antifungal Activity of BAL4815, a Novel Azole Against Dermatophytes and Emerging Non-Dermatophyte Fungi Including Zygomycetes (click for details)
In vitro activity of the new azole BAL4815 against clinical dermatophyte isolates (click for details)
In Vitro Activity of the New Azole BAL4815 against Clinical Candida Isolates Comprising Resistant C. albicans and Less Susceptible Candida spp (click for details)
Zygomycetes Hyphae are Less Susceptible to Killing by Polymorphonuclear Neutrophils (pmns) than Aspergillus Hyphae, through Toll-Like Receptor (tlr) Independent Mechanisms (click for details)
Identification of Proteins Co-Regulated with Cdr1p and Cdr2p in Association with the Acquisition of Azole Resistance in Clinical Isolates of Candida albicans by Proteomic Analysis (click for details)
Heteroresistance to Flucytosine (5FC) in Candida Species (click for details)
Evaluation of the Clinical and Laboratory Standards Institute (CLSI) M44-A Disk Diffusion Method for Determining Susceptibilities of 584 Clinical Isolates of Cryptococcus neoformans to Voriconazole (click for details)


Subscribe to ICAAC 45th